DUBLIN – The March meeting of the EMA's Committee for Human Medicinal Products (CHMP), the first to be held in its new home in Amsterdam, must have been a rather quiet affair. Just one new therapy was up for consideration – Bluebird Bio Inc.'s lentiglobin cell and gene therapy for beta-thalassemia – and it duly came out with a positive vote, which paves the way for a formal European Commission approval in the second quarter. The treatment, which comprises autologous CD34 cells transduced with a lentiviral vector, lentiglobin 3305, expressing a working copy of the beta-globin gene, will be marketed as Zynteglo.